|
|
Blood, 1 May 2005, Vol. 105, No. 9, pp. 3722-3730.
Prepublished online as a Blood First Edition Paper on January 13, 2005; DOI 10.1182/blood-2004-10-3999.
 Previous Article | Next Article 
Submitted October 18, 2004
Accepted December 31, 2004
Proteomic analysis of mantle cell lymphoma by protein microarray
Irene M Ghobrial, Daniel J McCormick, Scott H Kaufmann, Alexey A Leontovich, David A Loegering, Nga T Dai, Kelly L Krajnik, Mary J Stenson, Mona F Melhem, Anne J Novak, Stephen M Ansell, and Thomas E Witzig*
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Proteomic Core, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Department of Oncology, Mayo Clinic, Rochester, MN, USA
Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN, USA
Department of Oncology, Mayo Clinic, Rochester, MN, USA
Genomics Core, Molecular Biology, Mayo Clinic, Rochester, MN, USA
Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA, USA
* Corresponding author; email: Witzig.Thomas{at}mayo.edu.
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We employed antibody microarrays to compare patterns of protein expression between CD19+ purified B-lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a greater than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared to normal B-cell control. Seventy-seven polypeptides were overexpressed using the >1.3-fold cutoff and thirteen polypeptides were overexpressed using the 2-fold cutoff. These included cell cycle regulators (RCC1, MDM2), a kinase (CRIK), chaperone proteins (Hsp90, Hsp10), and phosphatase regulators (AKAP149, PP5 and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Psyrri, S. Papageorgiou, E. Liakata, A. Scorilas, D. Rontogianni, C. K. Kontos, P. Argyriou, D. Pectasides, N. Harhalakis, V. Pappa, et al.
Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Clin. Cancer Res.,
September 15, 2009;
15(18):
5724 - 5732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Boyd, R. Jukes-Jones, R. Walewska, D. Brown, M. J. S. Dyer, and K. Cain
Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma
Mol. Cell. Proteomics,
July 1, 2009;
8(7):
1501 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dal Col, P. Zancai, L. Terrin, M. Guidoboni, M. Ponzoni, A. Pavan, M. Spina, S. Bergamin, S. Rizzo, U. Tirelli, et al.
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Blood,
May 15, 2008;
111(10):
5142 - 5151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Gul, H. Basaga, and O. Kutuk
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures
Brief Funct Genomic Proteomic,
February 18, 2008;
(2008)
eln002v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Blood,
December 15, 2007;
110(13):
4417 - 4426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Madoz-Gurpide, M. Canamero, L. Sanchez, J. Solano, P. Alfonso, and J. I. Casal
A Proteomics Analysis of Cell Signaling Alterations in Colorectal Cancer
Mol. Cell. Proteomics,
December 1, 2007;
6(12):
2150 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kawamata, J. Chen, and H. P. Koeffler
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Blood,
October 1, 2007;
110(7):
2667 - 2673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al.
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
Blood,
June 1, 2007;
109(11):
4964 - 4972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Cancer Res.,
April 15, 2007;
67(8):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ripperger, N. von Neuhoff, K. Kamphues, M. Emura, U. Lehmann, M. Tauscher, M. Schraders, P. Groenen, B. Skawran, C. Rudolph, et al.
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle cell lymphomas
Haematologica,
April 1, 2007;
92(4):
460 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Schmitt, M. Gehrmann, M. Brunet, G. Multhoff, and C. Garrido
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
J. Leukoc. Biol.,
January 1, 2007;
81(1):
15 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Peponi, E. Drakos, G. Reyes, V. Leventaki, G. Z. Rassidakis, and L. J. Medeiros
Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma
Am. J. Pathol.,
December 1, 2006;
169(6):
2171 - 2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rudelius, S. Pittaluga, S. Nishizuka, T. H.-T. Pham, F. Fend, E. S. Jaffe, L. Quintanilla-Martinez, and M. Raffeld
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Blood,
September 1, 2006;
108(5):
1668 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Marzec, M. Kasprzycka, R. Lai, A. B. Gladden, P. Wlodarski, E. Tomczak, P. Nowell, S. E. DePrimo, S. Sadis, S. Eck, et al.
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
Blood,
September 1, 2006;
108(5):
1744 - 1750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Smith, M. B. Watson, S. L. O'Kane, P. J. Drew, M. J. Lind, and L. Cawkwell
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
2115 - 2120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ek, U. Andreasson, S. Hober, C. Kampf, F. Ponten, M. Uhlen, H. Merz, and C. A. K. Borrebaeck
From Gene Expression Analysis to Tissue Microarrays: A Rational Approach to Identify Therapeutic and Diagnostic Targets in Lymphoid Malignancies
Mol. Cell. Proteomics,
June 1, 2006;
5(6):
1072 - 1081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Hall, C. B. Todd, P. L. Hyland, S. S. McDade, H. Grabsch, M. Dattani, K. J. Hillan, and S.E. H. Russell
The Septin-Binding Protein Anillin Is Overexpressed in Diverse Human Tumors
Clin. Cancer Res.,
October 1, 2005;
11(19):
6780 - 6786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig
Current Treatment Approaches for Mantle-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6409 - 6414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
